article thumbnail

Vaccine successfully lowers cholesterol in preclinical studies

Drug Discovery World

New studies have demonstrated that Vaxxinity’s vaccine VXX-401 reproducibly lowers low-density lipoprotein cholesterol (LDL-C) in non-human primates. A cholesterol vaccine like VXX-401 may provide a cost-effective and widely deployable solution that could potentially benefit hundreds of millions of people at risk.

Vaccine 260
article thumbnail

Successful clinical trial for re-engineered Covid vaccine 

Drug Discovery World

The University of Queensland’s re-engineered clamp platform has produced a vaccine that is equally safe and virus-neutralising as an approved Covid vaccine considered among the best in its class. He said: “CEPI is striving towards vaccines being developed within 100 days of a new virus emerging: a goal known as the 100 Days Mission.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Accelerating recombinant protein vaccine discovery

Drug Discovery World

Vaccination responses need to be rapid, efficacious and cost-effective if they are to outpace new viral threats emerging across the globe, says Jian He (Jason) , Chemistry, Manufacturing and Controls (CMC) Head, WuXi Vaccines. This would give more people much faster access to more effective vaccines.

Vaccine 147
article thumbnail

World Tuberculosis Day 2024: New vaccines offer hope

Drug Discovery World

The vaccines currently in late-stage development hold promise in tackling the disease burden of tuberculosis (TB), says data and analytics company GlobalData on World Tuberculosis Day 2024. According to GlobalData, there are 11 vaccines in late-stage development for TB globally. TB remains a global pandemic, with 1.8

Vaccine 130
article thumbnail

AI tool predicts new viral variants and could improve vaccines

Drug Discovery World

The scientists say the tool can help inform the development of vaccines and therapies for SARS-CoV-2 and other rapidly mutating viruses. The University has also launched a new global consortium to research and develop next-generation Covid-19 and flu vaccines, backed by £8 ($9.8) million funding from UK Research and Innovation (UKRI).

Vaccine 264
article thumbnail

SLAS2024 update: The technology behind nanoparticle-based vaccines

Drug Discovery World

Dr Masaru Kanekiyo On Tuesday 6 February at 11.30am, the speaker will be Masaru Kanekiyo, DVM, PhD, Investigator and Chief of Molecular Immunoengineering Section of the Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID), NIH. See the full programme and register your interest in this event.

Vaccine 162
article thumbnail

Vaccine monitoring crucial as SARS-CoV-2 evolves, say researchers

Drug Discovery World

UK researchers have highlighted the importance of continued surveillance of emerging SARS-CoV-2 variants and vaccine performance as the virus continues to evolve. The researchers found that both vaccines generated neutralising antibodies against the most recent strain of Omicron, BA.2.86. strains after their booster vaccination.

Vaccine 130